Repligen Corp (RGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN)

RGEN 165.74

-0.4%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Curtis E. Bemis who wrote (217)	2/14/2000 11:27:00 AM
From: JMarcus	Read Replies (2) of 395

Today's press release about further solidification of RGEN's patent rights to using Secretin for treating autism included the following mention of new clinical evidence tending to corroborate the connection between low secretin levels and autism in children with gastrointestinal symptoms (which covers a large subset of the autism population): "A recent study published in the Journal of Pediatrics (Horvath et al, Journal of Pediatrics 135 (5): 559-63) showed that 75% of autistic children with gastrointestinal symptoms had a significantly greater pancreatic response to secretin compared to children without the disorder, suggesting lack of normal secretin stimulation in this subset of autistic patients. Conducted at the University of Maryland Medical Center, the study was designed to understand the underlying biology of secretin in autism." Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next